
Bristol Myers Squibb Company (NYSE:BMY – Free Report) – Zacks Research boosted their Q3 2027 earnings per share (EPS) estimates for Bristol Myers Squibb in a report issued on Wednesday, November 11th. Zacks Research analyst Team now forecasts that the biopharmaceutical company will post earnings of $1.74 per share for the quarter, up from their prior estimate of $1.55. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Bristol Myers Squibb’s current full-year earnings is $6.46 per share. Zacks Research also issued estimates for Bristol Myers Squibb’s FY2027 earnings at $6.41 EPS, Q1 2028 earnings at $1.36 EPS, Q2 2028 earnings at $1.25 EPS and Q3 2028 earnings at $1.16 EPS.
Several other equities research analysts have also recently weighed in on BMY. HSBC reissued a “hold” rating and issued a $65.00 price objective (up from $60.00) on shares of Bristol Myers Squibb in a research report on Thursday, September 10th. JPMorgan Chase & Co. boosted their target price on shares of Bristol Myers Squibb from $67.00 to $73.00 and gave the stock an “overweight” rating in a research report on Friday, July 31st. Wells Fargo & Company cut their target price on shares of Bristol Myers Squibb from $65.00 to $60.00 and set an “equal weight” rating for the company in a research note on Tuesday, October 13th. Morgan Stanley reduced their price target on shares of Bristol Myers Squibb from $41.00 to $40.00 and set an “underweight” rating for the company in a report on Friday, October 30th. Finally, Daiwa Securities Group increased their price target on shares of Bristol Myers Squibb from $53.00 to $66.00 and gave the company a “neutral” rating in a report on Tuesday, August 4th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, sixteen have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $65.46.
Check Out Our Latest Stock Analysis on BMY
Bristol Myers Squibb Stock Performance
Shares of NYSE BMY opened at $62.96 on Monday. Bristol Myers Squibb has a 12 month low of $45.26 and a 12 month high of $68.64. The company has a market cap of $128.69 billion, a P/E ratio of 10.00, a P/E/G ratio of 0.32 and a beta of 0.20. The business’s 50 day moving average is $61.82 and its two-hundred day moving average is $60.35. The company has a quick ratio of 1.44, a current ratio of 1.59 and a debt-to-equity ratio of 1.79.
Bristol Myers Squibb (NYSE:BMY – Get Free Report) last announced its earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 earnings per share for the quarter, beating the consensus estimate of $1.10 by $0.25. The firm had revenue of $13.07 billion during the quarter, compared to the consensus estimate of $12.72 billion. Bristol Myers Squibb had a return on equity of 60.48% and a net margin of 18.47%. The firm’s revenue for the quarter was up 6.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.63 EPS.
Bristol Myers Squibb Dividend Announcement
The firm also recently disclosed a quarterly dividend, which was paid on Monday, November 2nd. Stockholders of record on Friday, October 2nd were issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.0%. The ex-dividend date of this dividend was Friday, October 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 55.88%.
Insider Activity
In related news, Director Julia A. Haller sold 3,800 shares of the stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $63.31, for a total value of $240,578.00. Following the completion of the transaction, the director owned 30,279 shares of the company’s stock, valued at $1,916,963.49. This represents a 11.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Phil M. Holzer sold 500 shares of the firm’s stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total transaction of $33,750.00. Following the transaction, the senior vice president owned 16,862 shares of the company’s stock, valued at approximately $1,138,185. This represents a 2.88% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.05% of the stock is currently owned by insiders.
Institutional Investors Weigh In On Bristol Myers Squibb
A number of institutional investors have recently added to or reduced their stakes in the stock. Raffa Wealth Management LLC acquired a new stake in shares of Bristol Myers Squibb in the 3rd quarter valued at $67,000. WCG Wealth Advisors LLC increased its position in shares of Bristol Myers Squibb by 275.2% during the 3rd quarter. WCG Wealth Advisors LLC now owns 164,676 shares of the biopharmaceutical company’s stock worth $10,276,000 after purchasing an additional 120,787 shares in the last quarter. Worldquant Millennium Advisors LLC increased its position in shares of Bristol Myers Squibb by 107.5% during the 3rd quarter. Worldquant Millennium Advisors LLC now owns 4,182,293 shares of the biopharmaceutical company’s stock worth $260,975,000 after purchasing an additional 2,166,299 shares in the last quarter. TRB Wealth Management LLC increased its position in shares of Bristol Myers Squibb by 22.3% during the 3rd quarter. TRB Wealth Management LLC now owns 5,554 shares of the biopharmaceutical company’s stock worth $347,000 after purchasing an additional 1,012 shares in the last quarter. Finally, Bellevue Group AG lifted its holdings in Bristol Myers Squibb by 8,587.7% during the 3rd quarter. Bellevue Group AG now owns 105,642 shares of the biopharmaceutical company’s stock valued at $6,592,000 after purchasing an additional 104,426 shares during the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.
About Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease. The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.
Featured Articles
- Five stocks we like better than Bristol Myers Squibb
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
